Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera Post author:Sam Post published:January 25, 2018 Post category:BioPharma The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace You Might Also Like Otsuka Pharma Believes in Akebia, Commits Another $865 Million to Expand Anemia Deal April 25, 2017 Catalyst Biosciences To Present At 19th Annual BIO CEO & Investor Conference February 2, 2017 Rumors Swirl Again Over AstraZeneca PLC and This $4.4 Billion San Diego Biotech September 7, 2017
